PDK4 and cancer: As PDK4 is subject to frequent mutation, amplification and deep deletion as disclosed by TCGA pan-cancer atlas studies (querying 22,179 patients and 22,802 samples in 36 clinical studies)39,40 (Fig. 6h), the molecule represents an important predictor of disease progression in treatment-naive patients in clinical oncology41,42.